Home › NCT06983691

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* female (sex assigned at birth);
* ≥18 years of age at enrollment;
* diagnosed with HER2+ metastatic breast cancer (mBC);
* receiving treatment with tucatinib combined with capecitabine and trastuzumab;
* able to speak and read English

Exclusion Criteria:

* visual or hearing impairment;
* severe cognitive impairment;
* severe mental illness interfering with ability to participate

About the study

The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into clinical care to better support mBC patients. The main question the study aims to answer is: is the patient navigation program feasible and acceptable for mBC patients?

Participants will receive patient navigation sessions over about 6 weeks. Participants will also complete study assessments via electronic survey at baseline and at about 3 and 6 weeks after enrollment, with the last assessment occurring after completion of the patient navigation program sessions. Participants will also complete a post-program exit interview.

What is being tested

• Patient Navigation Program (behavioral)

Sponsor: Duke University · Participants: 26 · Started: Aug 11, 2026

Contact the study team

• Smrithi Divakaran, MPH · Phone: 919-681-7695
• Michael W Willis · Phone: 919-681-8437

Official record on ClinicalTrials.gov — NCT06983691

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.